RDIF signs agreements with partners in Vietnam to expand production of the Russian Sputnik V vaccine

Press release, 01.12.2021

Moscow, December 1, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces expansion of cooperation with partners in Vietnam aimed at production of the Russian Sputnik V vaccine against coronavirus and signing of new agreements.

RDIF, leading Russian pharmaceutical company Binnopharm Group and Vietnam’s T&T GROUP have signed an agreement to create a full-cycle production of Sputnik V in Vietnam. The signing took place during the visit of the President of Vietnam Nguyen Xuan Phuc to Russia.

RDIF, Vabiotech (that is already producing Sputnik V) and the Sovico investment group signed a cooperation agreement to expand its production and set up manufacturing of the one-shot Sputnik Light vaccine in Vietnam.

RDIF is actively working with Vietnam’s regulatory authorities to register Sputnik Light in the country.

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 million people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: Alexey.Urazov@rdif.ru

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133